AFP and Mistral AI announce global partnership to enhance AI responses with reliable news content
Agence France-Presse (AFP) and Mistral AI have formed a partnership that will provide Mistral's conversational AI assistant, Le Chat, with access to the full range of AFP's text stories. This collaboration will allow users to receive more informed and up-to-date responses, underpinned by content that meets the highest journalistic standards.
Agence France-Presse (AFP) and Mistral AI have formed a partnership that will provide Mistral's conversational AI assistant, Le Chat, with access to the full range of AFP's text stories. This collaboration will allow users to receive more informed and up-to-date responses, underpinned by content that meets the highest journalistic standards.
Anglais
01/29/2026 02:00
Toshiba Announces Sample Availability of Gate Driver for Bridge Circuits Driving High-Current Automotive Brushed DC Motors
Toshiba Electronic Devices & Storage Corporation ("Toshiba") has started providing engineering samples of “TB9104FTG,” a gate driver[1] for bridge circuits used in high-current automotive brushed DC motors, suitable for body system applications such as power back doors, power sliding doors, and power seats. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260128677664/en/Toshiba: TB9104FTG, a gate driver for bridge circuits used i...
02/10/2026 08:15
U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Takeda’s Oveporexton (TAK-861) as a Potential First-in-Class Therapy for Narcolepsy Type 1
Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) and granted Priority Review for oveporexton (TAK-861) for the treatment of narcolepsy type 1 (NT1). Oveporexton is an investigational oral orexin receptor 2 (OX2R)-selective agonist designed to address the underlying orexin deficiency that causes NT1 by restoring orexin signaling. The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date in the third quart...